The information on candidate cancer driver alterations available from public databases is often descriptive and of limited mechanistic insight, which poses difficulties for reliable distinction between true driver and passenger events. To address this challenge, we performed in-depth analysis of whole-exome sequencing data from cell lines generated by a barrier bypass-clonal expansion (BBCE) protocol. The employed strategy is based on carcinogen-driven immortalization of primary mouse embryonic fibroblasts and recapitulates early steps of cell transformation. Among the mutated genes were almost 200 COSMIC Cancer Gene Census genes, many of which were recurrently affected in the set of 25 immortalized cell lines. The alterations affected pathways regulating DNA damage response and repair, transcription and chromatin structure, cell cycle and cell death, as well as developmental pathways. The functional impact of the mutations was strongly supported by the manifestation of several known cancer hotspot mutations among the identified alterations. We identified a new set of genes encoding subunits of the BAF chromatin remodeling complex that exhibited Ras-mediated dependence on PRC2 histone methyltransferase activity, a finding that is similar to what has been observed for other BAF subunits in cancer cells. Among the affected BAF complex subunits, we determined Smarcd2 and Smarcc1 as putative driver candidates not yet fully identified by large-scale cancer genome sequencing projects. In addition, Ep400 displayed characteristics of a driver gene in that it showed a mutually exclusive mutation pattern when compared with mutations in the Trrap subunit of the TIP60 complex, both in the cell line panel and in a human tumor data set. We propose that the information generated by deep sequencing of the BBCE cell lines coupled with phenotypic analysis of the mutant cells can yield mechanistic insights into driver events relevant to human cancer development.

Biocev 1st Faculty of Medicine Charles University Prague Czech Republic

Deutsches Krebsforschungszentrum Heidelberg Germany

Dynamics of T cell Interactions Team Institut Cochin Inserm U1016 Paris France

Epigenetics Group International Agency for Research on Cancer Lyon France

Faculty of Medicine and Health University of Leeds LIGHT Laboratories Leeds UK

Molecular Mechanisms and Biomarkers Group International Agency for Research on Cancer Lyon France

Pathological Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Hollstein M, Alexandrov LB, Wild CP, Ardin M, Zavadil J. Base changes in tumour DNA have the power to reveal the causes and evolution of cancer. Oncogene 2017; 36: 158–167. PubMed PMC

Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet 2014; 15: 585–598. PubMed PMC

Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014; 24: 52–60. PubMed PMC

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546–1558. PubMed PMC

Youn A, Simon R. Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics 2011; 27: 175–181. PubMed PMC

Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res 2012; 22: 1589–1598. PubMed PMC

Gonzalez-Perez A, Lopez-Bigas N. Functional impact bias reveals cancer drivers. Nucleic Acids Res 2012; 40: e169. PubMed PMC

Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214–218. PubMed PMC

Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 2013; 29: 2238–2244. PubMed

Reimand J, Bader GD. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol 2013; 9: 637. PubMed PMC

Yeang CH, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J 2008; 22: 2605–2622. PubMed

Miller CA, Settle SH, Sulman EP, Aldape KD, Milosavljevic A. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. BMC Med Genomics 2011; 4: 34. PubMed PMC

Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 2012; 22: 398–406. PubMed PMC

Vandin F, Upfal E, Raphael BJ. De novo discovery of mutated driver pathways in cancer. Genome Res 2012; 22: 375–385. PubMed PMC

Zhao J, Zhang S, Wu LY, Zhang XS. Efficient methods for identifying mutated driver pathways in cancer. Bioinformatics 2012; 28: 2940–2947. PubMed

Leiserson MD, Blokh D, Sharan R, Raphael BJ. Simultaneous identification of multiple driver pathways in cancer. PLoS Comput Biol 2013; 9: e1003054. PubMed PMC

Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep 2013; 3: 2650. PubMed PMC

Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495–501. PubMed PMC

Leiserson MD, Vandin F, Wu HT, Dobson JR, Eldridge JV, Thomas JL et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet 2015; 47: 106–114. PubMed PMC

Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177–183. PubMed PMC

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674. PubMed

Odell A, Askham J, Whibley C, Hollstein M. How to become immortal: let MEFs count the ways. Aging (Albany NY) 2010; 2: 160–165. PubMed PMC

Stampfer MR, Bartley JC. Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. Proc Natl Acad Sci USA 1985; 82: 2394–2398. PubMed PMC

Severson PL, Vrba L, Stampfer MR, Futscher BW. Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen 2014; 775-776: 48–54. PubMed PMC

Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593–1603. PubMed

vom Brocke J, Schmeiser HH, Reinbold M, Hollstein M. MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 2006; 27: 2141–2147. PubMed

Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci USA 2004; 101: 2963–2968. PubMed PMC

Liu Z, Muehlbauer KR, Schmeiser HH, Hergenhahn M, Belharazem D, Hollstein MC. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 2005; 65: 2583–2587. PubMed

Nedelko T, Arlt VM, Phillips DH, Hollstein M. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer 2009; 124: 987–990. PubMed

Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallee MP et al. Modelling mutational landscapes of human cancers PubMed PMC

Feldmeyer N, Schmeiser HH, Muehlbauer KR, Belharazem D, Knyazev Y, Nedelko T et al. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat Res 2006; 608: 163–168. PubMed

Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C et al. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 2008; 27: 2788–2794. PubMed PMC

Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 2015; 517: 489–492. PubMed PMC

Gonzalez-Perez A, Jene-Sanz A, Lopez-Bigas N. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol 2013; 14: r106. PubMed PMC

Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 2013; 14: 765–780. PubMed

Helming KC, Wang X, Roberts CW. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 2014; 26: 309–317. PubMed PMC

Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010; 18: 316–328. PubMed PMC

Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med 2015; 21: 1491–1496. PubMed PMC

Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov 2014; 13: 828–851. PubMed PMC

Der CJ, Finkel T, Cooper GM. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 1986; 44: 167–176. PubMed

Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72: 2457–2467. PubMed PMC

Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2013; 45: 592–601. PubMed PMC

Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 2013; 8: e55119. PubMed PMC

Kim JE, Shin JS, Moon JH, Hong SW, Jung DJ, Kim JH et al. Foxp3 is a key downstream regulator of p53-mediated cellular senescence. Oncogene 2017; 36: 219–230. PubMed

Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 2013; 5: 197ra01. PubMed

Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature 2016; 538: 260–264. PubMed PMC

Celis JE. Cell Biology: A Laboratory Handbook3rd edElsevier Academic Press: Amsterdam, 2006. 4.

Liu Z, Belharazem D, Muehlbauer KR, Nedelko T, Knyazev Y, Hollstein M. Mutagenesis of human p53 tumor suppressor gene sequences in embryonic fibroblasts of genetically-engineered mice. Genet Eng (NY) 2007; 28: 45–54. PubMed

Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: P3. PubMed

Cancer Gene Census online. http://cancer.sanger.ac.uk/census.

Ensembl Variant Effect Predictor web interface. http://www.ensembl.org/vep.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401–404. PubMed PMC

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1. PubMed PMC

Chromatin Remodeler Smarca5 Is Required for Cancer-Related Processes of Primary Cell Fitness and Immortalization